Mineralcorticoid receptor antagonists for the treatment of endometriosis
OA: closed
AI-generated summary
This patent describes using mineralcorticoid receptor antagonists as improved therapeutic agents for endometriosis that offer better efficacy and side effect profiles while preventing bone mass loss.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
The aim of the present invention is the use of mineralcorticoid receptor antagonists for the production of a drug for the treatment of endometriosis. The present invention particularly relates to an improved therapeutic agent against endometriosis, which has a more favorable effectiveness profile and/or profile of side effects than previously available treatment therapies. With a mineralcorticoid receptor antagonist, endometriosis can be lastingly treated without resulting in a loss of bone mass.
My notes (saved in your browser only)
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.
Source provenance
- europepmc
- last seen: 2026-07-24T06:18:32.875334+00:00